DUARTE, Calif. -- City of Hope researchers participated in more than 50 studies on improvements to cancer treatment, patient care and clinical trials to be presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, running from June 3 through 7.
Research highlights include:
"Impact of neoadjuvant chemotherapy following chemoradiation on tumor response, adverse events and surgical complications in patients with advanced renal cancer treated with TME."
Monday, June 6, 8 a.m. to 12 p.m.
McCormick Place E450b
Discussion: 11:30 a.m. to 12:30 p.m., McCormick Place Hall D1
Study reveals rectal cancer patients benefit from having additional chemotherapy prior to surgery. Total mesorectal excision, in which a large portion of the bowel is removed, is considered the gold standard treatment for rectal cancers. Prior to surgery, patients often undergo neoadjuvant therapy with combined chemotherapeutic and radiation treatments. Patients who achieve a pathologic complete response to the neoadjuvant therapy have better expected outcomes from surgery, but a majority of patients do not show complete response, which prompts physicians to proscribe additional chemotherapy after surgery. Julio Garcia-Aguilar, M.D., Ph.D., chair of City of Hope's Department of Surgery, is the lead author of the multicenter study that examined how increasing cycles of chemotherapy in addition to chemoradiation prior to the surgery would impact a patient's complete response, treatment side effects and possible complications from surgery.
Three sequential phase II clinical trials enrolled a total of 175 patients with either stage II or III rectal cancer. The patients were treated with neoadjuvant chemoradiation, and then received different specified cycles of neoadjuvant chemotherapy, followed by total mesorectal excision.
"Patients who receive additional chemotherapy before
|Contact: Shawn Le|
City of Hope